Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 1, 2016, Pages 95-101

  Calvo Río, Vanesa ^a   Blanco, Ricardo ^a   Santos Gómez, Montserrat ^a   Rubio Romero, Esteban ^b   Cordero Coma, Miguel ^c   Gallego Flores, Adela ^d   Veroz, Raúl ^d   Torre, Ignacio ^e   Hernández, Félix Francisco ^f   Atanes, Antonio ^g   Loricera, Javier ^a   Gonzalez Vela M C ^a   Palmou, Natalia ^a   Hernández, José L ^h   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL DE LEÓN   (Spain)

^d Hospital de Merida   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f University General Hospital of Gran Canaria   (Spain)

^g Division of Rheumatology   (Spain)

^h UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Anti TNF therapy; Golimumab; Refractory; Spondyloarthritis; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE ANTERIOR UVEITIS; ADULT; ANKYLOSING SPONDYLITIS; ANTERIOR CHAMBER INFLAMMATION; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC ANTERIOR UVEITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN CELL; INFLAMMATION; INJECTION SITE REACTION; IRIDOCYCLITIS; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTERIOR CHAMBER INFLAMMATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SPONDYLARTHRITIS; UVEITIS; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TREATMENT OUTCOME; UVEITIS;

EID: 84962603668     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.03.002     Document Type: Article

References (66)

1. [1] Gladman, D.D., Psoriatic arthritis. Rheum Dis Clin North Am 24 (1998), 829–844.
2. [2] De Keyser, F., Elewaut, D., De Vos, M., De Vlam, K., Cuvelier, C., Mielants, H., et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 24 (1998), 785–813.
3. [3] Gladman, D., Spondyloarthropathies. Lahita, R., Weinstein, A., (eds.) Educational review manual in rheumatology, 2nd ed, 2002, Castle Connolly Graduate Medical, New York, 1–26.
4. [4] Healy, P.J., Helliwell, P.S., Classification of the spondyloarthropathies. Curr Opin Rheumatol, 17, 2005, 395.
5. [5] Mielants, H., Van den Bosch, F., Extra-articular manifestations. Clin Exp Rheumatol 27:Suppl. 55 (2009), S56–S61.
6. [6] Zeboulon, N., Dougados, M., Gossec, L., Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67 (2008), 955–959.
7. [7] Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc, N., Brandt, J., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68 (2009), 777–783.
8. [8] Rudwaleit, M., van der Heijde, D., Landewé, R., Akkoc, N., Brandt, J., Chou, C.T., et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70 (2011), 25–31.
9. [9] Levy-Clarke, G., Jabs, D.A., Read, R.W., Rosenbaum, J.T., Vitale, A., Van Gelder, R.N., et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121 (2014), 785–796.
10. [10] Rosenbaum, J.T., Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol 34 (2015), 999–1002.
11. [11] Muñoz-Fernández, S1, Hidalgo, V., Fernández-Melón, J., Schlincker, A., Bonilla, G., Ruiz-Sancho, D., et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30 (2003), 1277–1279.
12. [12] Dougados, M., Berenbaum, F., Maetzel, A., Amor, B., Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine. Rev Rhum Ed Fr 60 (1993), 81–83.
13. [13] Muñoz-Fernández, S., García-Aparicio, A.M., Hidalgo, M.V., Platero, M., Schlincker, A., Bascones, M.L., et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye 23 (2009), 1130–1133.
14. [14] Chang, J.H., McCluskey, P.J., Wakefield, D., Acute anterior uveitis and HLA-B27. Surv Ophthalmol 50 (2005), 364–388.
15. [15] Power, W.J., Rodriguez, A., Peroza-Seres, M., Foster, C.S., Outcomes in anterior uveitis associated with the HLAB27 haplotype. Ophthalmology 105 (1998), 1646–1651.
16. [16] Braun, J., Baraliakos, X., Listing, J., Sieper, J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52 (2005), 2447–2451.
17. [17] Sieper, J., Koenig, A., Baumgartner, S., Wishneski, C., Foehl, J., Vlahos, B., et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69 (2010), 226–229.
18. [18] Rudwaleit, M., Rødevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68 (2009), 696–701.
19. [19] Rosenbaum, J.T., Rudwaleit, M., Landewe, R., Marzo Ortega, H., Sieper, J., van der Heijde, D.M., et al. Observed incidence rates of uveitis over 96 weeks of certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Rheum 66 (2014), S10–S237.
20. [20] Galor, A., Perez, V.L., Hammel, J.P., Lowder, C.Y., Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 11 (2006), 2317–2323.
21. [21] Guignard, S., Gossec, L., Salliot, C., Ruyssen-Witrand, A., Luc, M., Duclos, M., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65 (2006), 1631–1634.
22. [22] Kay, J., Rahman, M.U., Golimumab: a novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 4 (2010), 159–170.
23. [23] Smolen, J.S., Kay, J., Doyle, M.K., Landewé, R., Matteson, E.L., Wollenhaupt, J., Gaylis, N., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009), 210–221.
24. [24] Emery, P., Fleischmann, R.M., Moreland, L.W., Hsia, E.C., Strusberg, I., Durez, P., et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis. Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60 (2009), 2272–2283.
25. [25] Faez, S., Lobo, A.M., Sobrin, L., Papaliodis, G.N., Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol 42 (2014), 392–395.
26. [26] Calvo-Río, V., de la Hera, D., Blanco, R., Beltrán-Catalán, E., Loricera, J., Cañal, J., et al. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 32 (2014), 864–868.
27. [27] Cordero-Coma, M., Calvo-Río, V., Adán, A., Blanco, R., Álvarez-Castro, C., Mesquida, M., et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm, 2014, 2014, 717598.
28. [28] Miserocchi, E., Modorati, G., Pontikaki, I., Meroni, P.L., Gerloni, V., Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22 (2014), 90–95.
29. [29] Miserocchi, E., Modorati, G., Pontikaki, I., Meroni, P., Gerloni, V., Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 31 (2013), 320–321.
30. [30] Cordero-Coma, M., Salom, D., Díaz-Llopis, M., López-Prats, M.J., Calleja, S., Golimumab for uveitis. Ophthalmology, 118, 2011, 1892.
31. [31] William, M., Faez, S., Papaliodis, G.N., Lobo, A.M., Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2 (2012), 231–233.
32. [32] Mesquida, M., Victoria Hernández, M., Llorenç, V., Pelegrín, L., Espinosa, G., Dick, A.D., et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21 (2013), 160–162.
33. [33] Van der Linden, S., Valkenburg, H., Cats, A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984), 361–368.
34. [34] Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., Mielants, H., CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54 (2006), 2665–2673.
35. [35] Díaz-Llopis, M., Salom, D., Garcia-de-vicuña, C., Cordero-Coma, M., Ortega, G., Ortego, N., et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119 (2012), 1575–1581.
36. [36] Calvo-Río, V., de la Hera, D., Beltrán-Catalán, E., Blanco, R., Hernandez, M., Martínez-Costa, L., et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32:4 Suppl. 84 (2014), S54–S57.
37. [37] Calvo-Río, V., Blanco, R., Beltrán, E., Sánchez-Bursón, J1, Mesquida, M1, Adán, A., et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet′s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53 (2014), 2223–2231.
38. [38] Deschenes, J., Murray, P.I., Rao, N.A., Nussenblatt, R.B., International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm 16 (2008), 1–2.
39. [39] The standardization of uveitis nomenclature (SUN) working group, Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. J Ophthalmol 140 (2005), 509–516.
40. [40] Nussenblatt, R.B., Palestine, A.G., Chan, C.C., Roberge, F., Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92 (1985), 467–471.
41. [41] Sampaio-Barros, P.D., Pereira, I.A., Hernández-Cuevas, C., Berman, A., Burgos-Vargas, R., Gutierrez, M.A., et al. An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clin Exp Rheumatol 31 (2013), 484–489.
42. [42] Maksymowych, W.P., Adlam, N., Lind, D., Russell, A.S., Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity. Clin Rheumatol 16 (1997), 461–465.
43. [43] Feldtkeller, E., Khan, M.A., van der Heijde, D., van der Linden, S., Braun, J., Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23 (2003), 61–66.
44. [44] Jaakkola, E., Herzberg, I., Laiho, K., Barnardo, M.C., Pointon, J.J., Kauppi, M., et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 65 (2006), 775–780.
45. [45] Bañares, A., Jover, J.A., Fernández-Gutiérrez, B., Benítez del Castillo, J.M., García, J., Vargas, E., et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum 40 (1997), 358–370.
46. [46] Rosenbaum, J.T., Characterization of uveitis associated with spondyloarthritis. J Rheumatol 16 (1989), 792–796.
47. [47] Sampaio-Barros, P.D., Conde, R.A., Bonfiglioli, R., Bértolo, M.B., Samara, A.M., Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int 26 (2006), 1143–1146.
48. [48] Durrani, K., Foster, C.S., Psoriatic uveitis: a distinct clinical entity?. Am J Ophthalmol 139 (2005), 106–111.
49. [49] Fraga, N.A., Oliveira Mde, F., Follador, I., Rocha, B., de, O., Rêgo, V.R., Psoriasis and uveitis: a literature review. An Bras Dermatol 87 (2012), 877–883.
50. [50] Rothova, A., Buitenhuis, H.J., Christiaans, B.J., Linssen, A., van der Gaag, R., Kijlstra, A., et al. Acute anterior uveitis (AAU) and HLA-B27. Br J Rheumatol 22 (1983), 144–145.
51. [51] Tay-Kearney, M.L., Schwam, B.L., Lowder, C., Dunn, J.P., Meisler, D.M., Vitale, S., et al. Clinical features and associated systemic diseases of HLA-B27 uveitis. Am J Ophthalmol 121 (1996), 47–56.
52. [52] Rothova, A., Suttorp-van Schulten, M.S., Frits Treffers, W., Kijlstra, A., Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996), 332–336.
53. [53] Wendling, D., Paccou, J., Berthelot, J.M., Flipo, R.M., Guillaume-Czitrom, S., Prati, C., et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 4 (2011), 503–510.
54. [54] Lim, L.L., Fraunfelder, F.W., Rosenbaum, J.T., et al. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56 (2007), 3248–3252.
55. [55] Riancho-Zarrabeitia, L., Calvo-Río, V., Blanco, R., Mesquida, M., Adan, A.M., Herreras, J.M., et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum, 2015, 21.
56. [56] Arida, A., Fragiadaki, K., Giavri, E., Sfikakis, P.P., Anti-TNF agents for Behçet′s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41 (2011), 61–70.
57. [57] Sobrin, L., KIM, E.C., Christen, W., Papadaki, T., Letko, E., Foster, C.S., Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125 (2007), 895–900.
58. [58] Santos Lacomba, M., Marcos Martín, C., Gallardo Galera, J.M., Gómez Vidal, M.A., Collantes Estévez, E., Ramírez Chamond, R., et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33 (2001), 251–255.
59. [59] Braun, J., de Keyser, F., Brandt, J., Mielants, H., Sieper, J., Veys, E., New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 13 (2001), 245–249.
60. [60] Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 6 (2002), 1187–1193.
61. [61] Poddubnyy, D., Rudwaleit, M., Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis—a five-year update. Expert Opin Biol Ther 13 (2013), 1599–1611.
62. [62] Kavanaugh, A., Mcinnes, I., Mease, P., Krueger, GG, Gladman, D, Gomez-Reino, J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60 (2009), 976–986.
63. [63] Inman, R.D., Davis, JC Jr, Heijde, Dv, Diekman, L., Sieper, J., Kim, S.I., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58 (2008), 3402–3412.
64. [64] Sandborn, W.J., Feagan, B.G., Marano, C., Zhang, H., Strauss, R., Johanns, J., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
65. [65] Schoels, M., Aletaha, D., Smolen, J.S., Wong, J.B., Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71 (2012), 1303–1308.
66. [66] Carmona, L., Abasolo, L., Descalzo, M.A., et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 41 (2011), 71–80.